Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 102 entries
View as:

Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03503786 Org: User:
Start: 04/01/18 End: 12/31/23 Due: 12/31/24

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01656551 Org: User:
Start: 08/31/12 End: 11/30/24 Due: 11/30/25

The ONCOCAMP Study

Phase: N/A Priority: Normal
NCT ID: NCT06270602 Org: User:
Start: 07/14/23 End: 07/31/26 Due: 07/31/27

Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT06886282 Org: User:
Start: 11/05/24 End: 08/31/26 Due: 08/31/27

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Phase: N/A Priority: Normal
NCT ID: NCT00657878 Org: User:
Start: 11/30/08 End: 12/31/23 Due: 12/31/24

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04397601 Org: User:
Start: 05/11/20 End: 05/11/24 Due: 05/11/25

CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00330746 Org: User:
Start: 11/30/05 End: 06/30/08 Due: 06/30/09

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06893861 Org: User:
Start: 07/06/23 End: 07/31/25 Due: 07/31/26

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06509126 Org: User:
Start: 06/12/24 End: 06/30/28 Due: 06/30/29

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00415779 Org: User:
Start: 07/31/06 End: 07/31/09 Due: 07/31/10

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04310176 Org: User:
Start: 05/24/19 End: 11/30/24 Due: 11/30/25

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT00526643 Org: User:
Start: 11/30/07 End: 12/31/12 Due: 12/31/13

Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE)

Phase: N/A Priority: Normal
NCT ID: NCT04726228 Org: User:
Start: 06/21/21 End: 06/30/25 Due: 06/30/26

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00996983 Org: User:
Start: 09/30/09 End: 12/31/24 Due: 12/31/25

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06714357 Org: User:
Start: 03/12/25 End: 06/20/27 Due: 06/20/28

MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05233982 Org: User:
Start: 12/09/21 End: 01/31/26 Due: 01/31/27

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01359956 Org: User:
Start: 04/30/02 End: 02/28/11 Due: 02/28/12

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00997009 Org: User:
Start: 10/31/09 End: 12/31/24 Due: 12/31/25

BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00540800 Org: User:
Start: 02/29/04 End: 12/31/09 Due: 12/31/10

Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study

Phase: N/A Priority: Normal
NCT ID: NCT04123925 Org: User:
Start: 06/12/18 End: 09/02/19 Due: 09/02/20

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

Phase: N/A Priority: Normal
NCT ID: NCT05818865 Org: User:
Start: 01/18/21 End: 01/31/25 Due: 01/31/26

Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies

Phase: N/A Priority: Normal
NCT ID: NCT05818020 Org: User:
Start: 03/02/20 End: 06/30/22 Due: 06/30/23

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT01706120 Org: User:
Start: 10/31/12 End: 12/31/24 Due: 12/31/25

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Phase: N/A Priority: Normal
NCT ID: NCT04139772 Org: User:
Start: 09/01/19 End: 07/01/24 Due: 07/01/25

Molecular Data and Their Correlations With Clinical Outcomes in Gynecological Cancer Patients.

Phase: N/A Priority: Normal
NCT ID: NCT05733793 Org: User:
Start: 06/16/21 End: 06/16/25 Due: 06/16/26